NVAX
Novavax Inc.
Company Overview
| Mkt Cap | $1.21B | Price | $10.31 |
| Volume | 6.00M | Change | +11.89% |
| P/E Ratio | 2.7 | Open | $9.38 |
| Revenue | $1.1B | Prev Close | $9.21 |
| Net Income | $440.3M | 52W Range | $6.13 - $11.97 |
| Div Yield | N/A | Target | $14.11 |
| Overall | 50 | Value | 60 |
| Quality | 36 | Technical | 54 |
No chart data available
About Novavax Inc.
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Latest News
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK), Novavax (NVAX) and Airsculpt Technologies (AIRS)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVAX | $10.31 | +11.9% | 6.00M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |